Angiogenesis

– New studies to focus on speed of healing and molecular profiling of tissue regeneration induced by oat-derived bioactive products – EDMONTON, Alberta, July 18, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”…

Invitation to a Free Luncheon Presentation in Jeddah, Saudi Arabia, on Monday, October 31, 2022, at 1:00 pm (13:00) View Preliminary Human Data after 30 Days Treatment of Parkinson’s Disease Patients with FGF-1 at:…

ALPHARETTA, Ga., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced…

Professor Gemmy Cheung, Singapore Eye Research Institute, presented prespecified subgroup analysis of PCV patients enrolled in Opthea’s Phase 2b clinical trial of OPT-302 in combination with ranibizumab (Lucentis®), compared to ranibizumab…

ALPHARETTA, Ga., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS), announced…

Progression-free survival (PFS) in extrapancreatic neuroendocrine tumors (NETs) improved significantly with the addition of an angiogenesis inhibitor to standard endocrine therapy,…

– Research focused on addressing root cause of disease and tissue damage for diseases such as COVID-19 – – Leveraging the unique expertise and methods developed by the Angiogenesis Foundation to conduct pre-clinical studies to…

LAS VEGAS, June 17, 2021 (GLOBE NEWSWIRE) -- Zhittya Genesis Medicine, Inc. (a private company) (“Zhittya” or the “Company”), is proud to announce that Mr. Daniel C. Montano, CEO, and founder of Zhittya Genesis Medicine Inc. has received…